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Abstract
Condensed Abstract—In a population-based case-control study in the U.S., we examined risks
of histologically confirmed esophageal and gastric adenocarcinomas in relation to polymorphisms
of the following genes: GSTP; GSTM1; GSTT1; NAT1; and CYP1A1. For the GSTP1 Val/Val
genotype (vs. Ile/Ile), the respective ORs of esophageal, cardia, and other gastric adenocarcinomas
were 1.73 (0.75–4.02), 1.46 (0.57–3.73), and 1.22 (0.48–3.09), while no consistent patterns of
elevated risk were associated with the null GSTM1 or GSTT1 genotypes, one or two copies of
NAT1*10 or *11 alleles, or CYP1A1 Val/Val or Ile/Val genotypes (vs. Ile/Ile).
Background—Polymorphisms in glutathione-S-transferase (GST), N-acetyltransferase (NAT) 1,
and CYP1A1 genes have been suggested as susceptibility factors for esophageal and gastric
adenocarcinomas, but have not been consistently linked to elevated risks. In a population-based
case-control study, we examined risks in relation to polymorphisms of the following genes: GSTP;
GSTM1; GSTT1; NAT1; and CYP1A1.
Methods—Histologically confirmed incident cases, ages 30–79, were identified in three U.S.
locations. Population controls from the same catchment areas were frequency matched to expected
age and sex distributions of esophageal and gastric cardia adenocarcinomas. DNA was extracted
from buffy coat for PCR-based assays, with interpretable genotyping results obtained from 209
controls, 67 esophageal adenocarcinomas, 60 gastric cardia adenocarcinomas, and 56 noncardia
gastric adenocarcinomas. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated
among whites, adjusting for age, sex, and study center.
Results—In all histologic subgroups, ORs were somewhat elevated for the GSTP1 Val/Val
genotype (vs. Ile/Ile), although 95% CIs included 1.00. The respective ORs for esophageal, cardia,
and other gastric adenocarcinomas were 1.73 (0.75–4.02), 1.46 (0.57–3.73), and 1.22 (0.48–3.09).
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No consistent patterns of elevated risk were associated with the null GSTM1 or GSTT1 genotypes,
one or two copies of NAT1*10 or *11 alleles, or CYP1A1 Val/Val or Ile/Val genotypes (vs. Ile/Ile).
Conclusions—Additional research in larger samples is needed to further assess polymorphisms
and their interactions with epidemiologic risk factors, particularly for esophageal adenocarcinoma,
which has been increasing markedly in incidence.
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Introduction
Adenocarcinomas of the esophagus and stomach have diverse incidence patterns and risk
factors [1], but cigarette smoking has been associated with both in some studies [2–4].
Polymorphisms in the glutathione-S-transferase (GST) and N-acetyltransferase (NAT) 1
genes, which are involved in Phase II detoxification of certain tobacco carcinogens, have
been suggested as susceptibility factors but have not been consistently linked to elevated
risks [5]. Similarly, CYP1A1, a cytochrome P450 gene encoding Phase I detoxification
enzymes also involved in tobacco metabolism, has been inconsistently associated with
elevated cancer risks across different ethnic populations [6].
To further understand these associations, in a population-based case-control study of upper-
digestive tract cancers, we examined the risk of esophageal, gastric cardia, and other gastric
adenocarcinomas in relation to polymorphisms in the following genes: GSTP1 (chromosome
11q13); GSTM1 (1p13.3); GSTT1 (22q11.2); NAT1 (8p22); and CYP1A1 (15q22).
Materials and Methods
In 1993–95, histologically confirmed cases ages 30–79 years were identified by rapid
ascertainment in three U.S. locations following Institutional Review Board approvals at the
collaborating institutions [2], and written informed consent from each subject. Controls were
selected from the same catchment areas by random-digit dial if under age 65 years or from
the Medicare sampling frame if 65 or older. Cases and controls were frequency matched to
expected age and sex distributions of esophageal and gastric cardia adenocarcinomas. The
New Jersey study center also matched on race (white or non-white). Subjects in two of three
geographic locations (western Washington and 9 of the 15 participating counties in New
Jersey) were asked to provide 30 ml blood samples at the time of interview. About 30% of
cases and 4% of controls died prior to interview, and samples were obtained from
approximately two-thirds of both interviewed cases and controls. The questionnaire
ascertained demographic characteristics and information about exposures, including lifestyle
factors, height and weight, medication, and medical history.
DNA was extracted from buffy coat for genotyping. The presence of the GSTM1 and GSTT1
alleles, as well as the GSTM1*0/*0, and GSTT1 *0/*0 genotypes, was detected by
polymerase chain reaction [7,8], and a TaqMan assay was used to differentiate the GSTP1
Val/Val, GSTP1 Ile/Val, and GSTP1 Ile/Ile genotypes [8,9]. A PCR/DNA sequencing-based
assay, using PCR and dye terminator-cycle sequencing, was used to detect the genetic
polyadenylation variants within the 3′ flanking region of the NAT1 gene. Amplification
using specific oligonucleotide primers [10] and optimized thermal cycling conditions
yielded a single 345 base-pair PCR product. Alignment of the DNA sequence with the
published wild type sequence [11] using DNA sequence alignment software-enabled
identification of the NAT1*3, NAT1*10, and NAT1*11 alleles. Absence of these three
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variants is hereinafter referred to as NAT1*4+, which includes the wild type *4 plus new
variants not detected by the assay.
The CYP1A1 Ile462Val alleles were identified using an oligonucleotide ligation-based
genotyping assay [12]. The PCR primers utilized in this assay were as follows:
Forward primer: 5′-gTCTCCCTCTggTTACAggA-3′
Reverse primer: 5′-gAAAgACCTCCCAgCgggCA-3′
The reporter oligonucleotide probes were as follows:
Common reporter probe: 5′-TTgCCCgCTgggAggTCTTTC-3′
Wildtype allele probe: 5′-ggAAgTgTATCggTgAgACCA-3′
Mutant allele probe: 5′-ggAAgTgTATCggTgAgACCg-3′
The Ile/Val and Val/Val categories were collapsed for analysis due to insufficient numbers
of the Val/Val genotype.
Among whites who provided blood, interpretable genotyping results were obtained for up to
209 controls (98%), 67 cases (100%) with esophageal adenocarcinoma, 60 (98%) with
gastric cardia adenocarcinoma, and 56 (98%) with noncardia gastric adenocarcinoma,
although final numbers differed slightly by assay (see Table 1). Numbers of nonwhites (13,
2, 1, and 12, respectively) were too small to obtain separate risk estimates, and the
distribution of genotypes may vary by race [13]. Thus, these individuals were excluded from
analysis.
For genotypes with three or more categories (i.e., NAT1 and GSTP1), tests for Hardy-
Weinberg equilibrium in controls were conducted using SAS/GENETICS Proc Allele (SAS
9 product documentation available from http://v9doc.sas.com/sasdoc/). In unconditional
logistic regression analysis, odds ratios (ORs) and 95% confidence intervals (CIs) were
calculated, adjusting for age as a continuous variable, sex, and study center. Alcohol
consumption, smoking, and body mass index (BMI) did not alter the associations with
polymorphisms, and therefore, were not adjusted for in the models. Separate models
containing interaction terms were used to test for interactions of genotype with smoking
(ever vs. never), age (<60 vs. ≥60 years), and sex. An esophageal adenocarcinoma model
also included an interaction term for genotype and BMI (<median vs. ≥ median, sex-
specific). Analyses with pack-year, age, and BMI quartiles did not alter the conclusions,
therefore we collapsed the variables.
Results
The respective median ages for controls and esophageal, gastric cardia, and other cardia
adenocarcinoma cases were 66, 63, 66, and 67 years. Among controls, women were less
likely than men to have blood available for genotyping (35% vs. 50%; p=.01). Otherwise,
DNA availability did not differ by risk factor distribution between histologic subgroups of
cases and controls.
There was no departure from Hardy-Weinberg equilibrium for GSTP1 (p=0.76) or NAT1
(p=0.87) in control subjects. As shown in Table I, there were no consistent patterns of
elevated risk associated with the null GSTM1 or GSTT1 genotypes nor with one or two
copies of NAT1*10 or *11 alleles (whereas the NAT1*3 allele was not detected in any cases
or controls). In all histologic subgroups, ORs were somewhat elevated for the GSTP1 Val/
Val genotype (vs. Ile/Ile), although 95% CIs included 1.00. The respective ORs for
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esophageal, cardia, and other gastric adenocarcinomas were 1.73 (95% CI=0.75–4.02), 1.46
(0.57–3.73), and 1.22 (0.48–3.09). Associations were also null for CYP1A1 Val/Val and Ile/
Val genotypes. There were no statistically significant interactions of genotype with the
major risk factors examined (data not shown).
Discussion
This study found no evidence that the risk of adenocarcinomas of the esophagus or gastric
cardia or noncardia stomach varies with GSTP1, GSTM1, or GSTT1 genotype, nor does it
vary with the NAT1 or CYP1A1 polymorphisms examined. These results are consistent with
most upper-digestive cancer studies of GSTT1 and some studies of GSTP1, GSTM1, NAT1,
and CYP1A1. Previous gastric cancer studies generally found no association with GSTP1
variants, whereas about one-half reported associations with GSTM1 [5], and one reported an
inverse age-dependent association with GSTT1 [14]. Associations of esophageal cancer with
GSTM1, GSTP1, and GSTT1 were also equivocal [15–21]. The NAT1*10 variant has been
associated with elevated and decreased risks of gastric adenocarcinoma [22], whereas its
etiologic role in esophageal cancer remains unexplored. The CYP1A1 variant examined here
has been associated with esophageal cancer in Chinese, but not Japanese populations [6,23].
Possible explanations for contrasting study results include sample size and power
differences, ethnic variation, and random scatter around the null hypothesis.
The ORs in this study may reflect true null associations or low statistical power due to
limited availability of blood for genotyping. For example, with the available sample size,
this study has a power of .70 (allowing for a two-sided .05 Type I error rate) to detect a true
OR of 2.66 for esophageal adenocarcinoma among individuals with the GSTP1 Val/Val
genotype (vs. Ile/Ile). Detectable ORs of cardia and noncardia gastric adenocarcinoma are
2.94 and 2.82, respectively. Given the exploratory purpose of this study, however, the results
contribute to the limited literature on genetic polymorphisms for these cancers and suggest
that further consideration of the GSTP1 association may be warranted. Given the small
numbers, associations with the CYP1A1 Val/Val genotype, which is rare in most populations
[6], could not be assessed. An additional limitation may be potential selection bias related to
DNA availability. Specifically, blood was not collected from study subjects who died before
interview, which is often a limiting factor in case-control studies of cancers with short
survival time. Also, one-third of cases and controls approached for blood collection did not
provide samples, and female controls were significantly less likely to provide blood than
male controls. Strengths of this study include the population-based case-control design and
assessment of three histologic subtypes. Also to our knowledge, it is the first study to
evaluate NAT1 polymorphisms in esophageal adenocarcinoma. In this regard, since the
NAT1 genotyping associated with this study was completed, many other NAT1
polymorphisms are now listed in various SNP databases (Entrez SNP available from
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=snp).
Further research in larger samples is needed to assess interactions of additional genetic
polymorphisms and epidemiologic risk factors, particularly for esophageal adenocarcinoma,
which has been increasing markedly in incidence [24,25].
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